Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.240
+0.140 (12.73%)
At close: Aug 22, 2025, 4:00 PM
1.320
+0.080 (6.42%)
After-hours: Aug 22, 2025, 7:59 PM EDT
Prelude Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Prelude Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $4.00, which forecasts a 222.58% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $5.00.
Price Target: $4.00 (+222.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prelude Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +141.94% | Aug 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +303.23% | May 5, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $4 | Buy | Reiterates | $4 | +222.58% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +303.23% | Apr 8, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $4 | Buy | Reiterates | $4 | +222.58% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
n/a
from 7.00M
Revenue Next Year
n/a
EPS This Year
-1.59
from -1.68
EPS Next Year
-1.18
from -1.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.29 | -0.41 | -0.27 | ||
| Avg | -1.59 | -1.18 | -0.92 | ||
| Low | -1.69 | -1.51 | -1.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.